Restricted replication of the HIV-1 T-lymphotropic isolate NL4-3 in HL-60 cells  by Pise-Masison, Cynthia A. & Holland, Christie A.
VIROLOGY 206, 641--645 (1995) 
Restricted Replication of the HIV-1 T-Lymphotropic Isolate NL4-3 in HL-60 Cells 
CYNTHIA A, PIsE-MAslSON*'I  AND OHRISTIE A. HOLLAND1 '1 
*Department of Molecular Genetics and Microbiology, University of Massachusetts Medical Center, Worcester, Massachusetts, 
and fCenter for Virology, Immunology and Infectious Disease Research, Children's National Medical Center, Washington, DC 20010 
Received April 19, 1994; accepted September 30, 1994 
To understand how different cell types might influence the generation of viral variants, we have examined the differences 
in the viral life cycle of the HIV-1 isolate, NL4-3, in the human promyelocytic ell line, HL-60, and the human T cell line, H9. 
NL4-3 harvested from H9 cells productively infected and was cytopathic to H9 and HL-60 cells. However, the eytopathic 
effect was delayed in HL-60 cells compared to that seen in H9 cells, suggesting that NL4-3 replication was restricted in 
myeloid cells. This restriction was overcome by production of a variant virus, NL4-3 (M), which replicated efficiently in HL- 
60 cells. Measurements of the kinetics of entry of NL4-3 in H9 and HL-60 cells and NL4-3 (M) in HL-60 cells demonstrated 
that the timing of viral entry into each cell line was similar. However, quantitation of the amount of newly reverse-transcribed 
NL4-3 DNA in H9 and HL-60 cells revealed that NL4-3-infected H9 cells and NL4-3 (M)-infected HL-60 cells contained 
consistently more newly reverse-transcribed DNA than NL4-3-infected HL-60 cells. This difference was further amplified 
by inefficient spread of the virus throughout he HL-60 culture. Together these results suggest that the efficiency of NL4- 
3 infection of HL-60 cells is restricted at early steps in the viral life cycle and may be restricted at late steps as well. 
© 1995 Academic Press, Inc. 
A complex population of highly related but distinct HIV- 
1 isolates, termed quasispecies, is found in infected indi- 
viduals (1-10). The many isolates that replicate in the 
patient simultaneously might have different biological 
phenotypes and the separate but coordinated effect of 
these multiple quasispecies may have important implica ~ 
fions for pathogenesis in a complex disease such as 
AIDS. As a first step in defining the cellular pressures 
that control the changing composition of quasispecies, 
we examined various stages of the viral life cycle of HIV 
NL4-3 (11) in the human promyelocytic cell line, HL-60, 
compared to the life cycle of the virus in the human T 
cell line, H9. 
We previously reported that HIV-1 infection of HL-60 
cells initially results in expression of viral proteins on 
only a small percentage of cells and in production of 
low levels of cell-free reverse transcriptase activity (12). 
Fifteen or more days after HIV-1 infection of HL-60 cells, 
a decrease in viability of the culture occurred with a 
concomitant increase in the percentage of cells express- 
ing viral proteins to levels equivalent to HIV-l-infected 
H9 cells (12). 
We hypothesize that during the restricted replication 
of NL4-3 in HL-60 cells, a viral variant is produced by 
random mutation that efficiently replicates in HL-60 cells 
and is highly cytopathic for HL-60 cells. To test this hy- 
pothesis, virus was collected 30 days after infection of 
HL-60 cells with NL4-3 and titered on 08166 cells as 
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described (12). This virus, called NL4-3 (M), was then 
used to infect Hg, HL-60, and PLB986 cells (12, 13) at 
fixed multiplicity of infection (m.o.i.). In parallel, NL4-3 
harvested 7 days after infection of H9 cells was used to 
infect these cells at the same m.o.i. The viabilities of the 
cultures were monitored for 30 days by vital dye exclu- 
sion (Fig. 1). NL4-3 harvested from H9 cells and NL4-3 
(M) harvested from HL-60 cells had similar cytopathic 
effects on H9 cells (Fig. 1). Surprisingly, the cytopathic 
effects of NL4-3 and NL4-3 (M) on HL-60 cells were strik- 
ingly different. However, each virus had a similar cyto- 
pathic effect on both the myeloid ceil lines used, HL-60 
and PLB985. NL4-3 infection resulted in the death of both 
HL-60 and PLB986 cells (•2) with a mean survival time 
(MSso) of 25 and 20 days, respectively. NL4-3 (M) rapidly 
killed both HL-60 and PLB985 cells (MS50 = 8 days) (Fig. 
1). These data suggest that a viral variant is produced 
in HL-60 cells which is cytopathic to both HL-60 and 
PLB985 cells. 
To assay the efficiency of viral spread in HL-60 and 
H9 cells, total RNA was isolated from NL4-3 (M)- and 
NL4-3-infected cultures at various times after infection 
(2•). Each RNA sample was analyzed using a Northern 
blot and probed with a 32p-labeled DNA Aval fragment 
(8.0 kb) from pNL4-3. Three forms of HIV-1 RNA (9.7, 4.4, 
and 2.2 kb) were detected in NL4-3-infected H9 cells 
and NL4-3 (M)-infected HL-60 cells 5 days after infection 
(data not shown). NL4-3 RNA was detected in infected 
HL-60 cultures at times later than 15 days postinfection. 
These data are consistent with restricted replication of 
NL4-3 in HL-60 cells that results in a low efficiency of 
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FIG. 1. Viral adaptation. Cell-free virus was harvested from NL4-3 
infected HL-60 cells during the rapid phase of cell death (30 days after 
infection). H9 (squares), PLB985 (triangles), and HL-60 (circles) cells 
were infected with either NL4-3 harvested from infected H9 ceils (filled 
symbols) or NL4-3 (M) harvested from infected HL-60 cells (open sym- 
bols) at a m.o.i, of 0.2 TOlD/cell. The plus symbols are the data obtained 
from HL-60 cells cultured in supernatants harvested from uninfected 
cultures. 
viral recruitment of the culture. Furthermore, the variant 
virus, NL4-3 (M) has overcome this restriction and is 
capable of efficient viral recruitment of HL-60 cells. 
To test whether this observation was specific for NL4- 
3, the experiment was repeated using other cloned HIV- 
1 isolates, tllB and PM213 (12). The results were indistin- 
guishable from those shown in Fig. 1 (data not shown). 
Therefore, the production of a variant virus was not 
unique to the HIV-1 NL4-3 isolate and probably reflects 
a biological process of viral adaptation or selection of a 
cytopathic HIV-1 variant in HL-60 cells. 
To determine if the cytopathic phenotype of the HL- 
60-adapted variant, NL4-3 (M), was stable, the virus was 
propagated for 10 days through two sequential rounds 
of infection of H9 cells. Virus harvested at Day 5 after 
the second passage in H9 ceils was used to infect both 
H9 and HL-60 cells. The cytopathic effect of that virus 
was identical to that of NL4-3 (M) shown in Fig. 1. These 
results indicate that the change in the biological pheno- 
type is stable and that it is not selected against by growth 
in H9 cells, in addition, these results rule out the possibil- 
ity that the increased cytopathic effect of NL4-3 (M) was 
due to cytokines or other factors produced by HL-60 
cells. 
To determine if the delayed cytopathic effect of NL4- 
3 on HL-60 cells was due to a delay in the timing of entry 
of the virus into HL-60 cells, NL4-3 was used to infect 
both H9 and HL-60 ceils and compared to NL4-3 (M)- 
infected HL-60 cells. Leu3a (240 ng/ml), a monoclonal 
antibodyto CD4, was added at timed intervals after infec- 
tion to block viral entry. In addition to Leu3a, ddC (2 tiM) 
was added to the culture 24 hr after infection to prevent 
reverse transcription and viral spread. In the presence 
of these two inhibitors, only virus that enters the cell and 
is reverse transcribed before the addition of Leu3a and 
ddC can complete viral replication and score positively 
for viral surface antigen expression by indirect immune- 
fluorescence (IFA) using an HIV-1 + pooled patient serum. 
This assay depends upon the ability of the virus to com- 
plete the late steps in the viral life cycle and requires 
expression of viral proteins. It has been used by other 
investigators to determine the entry rates of HIV-1 into 
various cell lines (14). To determine the maximum num- 
ber of virus-expressing cells and exclude effects of differ- 
ences in late steps in the viral life cycle, two time points, 
60 and 72 hr postinfection, were scored and an average 
of the two time points were plotted (Fig. 2). The maximum 
percentage of virus-expressing cells in NL4-3-infected 
H9 cultures (14%) was 3.5- or 2.3-fold higher than in NL4- 
3-infected HL-60 cultures (4%) or NL4-3 (M)-infected HL- 
60 cultures (6%), respectively. The entry time, defined as 
the time point of Leu3a addition at which 50% of the 
maximum IFA-positive cells are observed, was deter- 
mined to be between 4 and 4.5 hr for NL4-3 and NL4-3 
(M) in either H9 and HL-60 cells. This time for viral entry 
into H9 cells is consistent with that previously reported 
by Srivastava and co-workers (14). Therefore, differences 
in the timing of entry cannot explain the 10- to 15-day 
delay in the life cycle of the virus in HL-60 cells. 
Once the virus has entered the cell, its RNA genome 
is uncoated and reverse transcribed into DNA. To see if 
this step was delayed in NL4-3-infected HL-60 cells, we 
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FIG. 2. HIV-1 entry. To determine if NL4=3 enters H9 and HL-60 cells 
at a similar rate, a time course of escape from Leu3a block was per- 
formed. H9 (open squares) or HL-60 (filled squares) cells were infected 
with NL4-3 at time zero and compared to HL-60 cells infected with 
NL4~3 (M) (filled circles) at time zero. 
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FiG. 3. Detection of newly reverse-transcribed DNA in infected H9 and HL-60 cells. H9 or HL-60 cells were infected with DNase-treated NL4-3 
at a m.o.i, of 0.25 TCID/cell. Cell lysates were prepared at various time points after infection. (A) PCR analysis was performed on cell lysates (6 x 
104 cells) using the pNL4-3-specific primer pair R1/NC1, R1, 5'-GGCTAACTAGGGAACCCACTGCTFAA-3' (nt 496 to nt 518); end NO1, 5'-CCGAGTCCT- 
GOGTCGAGAGATC-3' (nt 680 to nt 701). Cell lysates taken 2 hr after infection of HL-60 cells pretreated with 2 #M ddC were also amplified to 
control for DNase treatment. (B) Lysates from H9 and HL-60 ceils were amplified using ~-globin primer pair 1, 2. (C) Cell lysates from NL4-3- 
infected H9 and HL-60 cells and NL4-3 (M)-infected HL-60 cells (6 hr after infection) were serially diluted with uninfected HL-60 cell lysate. Lanes 
2, 5, and 8 represent PCR products from undiluted cell lysates, lanes 3, 6, and 9 represent PCR products from a 1,10 dilution of cell lysate, and 
lanes 4, 7, and 10 represent PCR products from a 1,100 dilution of cell lysate. Lane 1 represents PCR products from undiluted cell lysate of mock- 
infected cells. (D) Dilutions of 8E5 cells with uninfected HL-60 cells were used as DNA standards (lane 1, 60,000 8E5 cells; lane 2, 6000 8E5 cells; 
lane 3, 600 8E6 ceils; lane 4, 60 8E5 cells; and lane 5, 6 8E5 cells). Shown are the results from one of four identically performed experiments. 
performed a PCR analysis assay for the presence of 
newly reverse transcribed DNA in NL4-3 infected H9 and 
HL-60 cells at timed intervals after infection (15). Briefly, 
NL4-3 virions were treated with DNase to el iminate non- 
specific DNA sequences carried on the surface of virions 
(15, 16) and used to infect H9 and HL-60 cells. Lysates 
of the infected cells were prepared at timed intervals 
after infection. As a control, HL-60 cells pretreated with 
2 #M ddC for 15 rain to block reverse transcription were 
infected with PNase-treated NL4-3, Lysates were pre- 
pared 2 hr after infection. An aliquot of each lysate was 
then PCR amplif ied using /~-globin-specific primer pair 
primer 1 and primer 2 (Perkin Elmer, Cetus) to quantitate 
the amount of DNA in the lysate (Fig. 3B). Appropriate 
amounts of each lysate were then PCR amplif ied and the 
products analyzed for the presence of newly reverse- 
transcribed viral DNA using primer pair R1/NC1. This 
primer pair amplif ies a 206-bp fragment at the R/5' non- 
coding sequence junction (15). The noncoding region is 
3' to the primer binding site and thus the products of this 
amplif ication represent ewly reverse4ranscribed DNA, 
Two hours after infection viral DNA was detected in 
both infected H9 and HL-60 cells but not ddC-treated HL- 
60 cells (Fig. 3A). In infected H9 cells, a high level of. 
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newly reverse-transcribed DNA is detected continuously 
over 5 days, consistent with a spreading infection in H9 
cells (Fig. 3A). The results are different in HL-60 cells, 
where newly reverse-transcribed DNA decreases pro- 
gressively over the 7 days examined. These data are 
also consistent with a restriction in the spread of the 
virus in the HL-60 culture. 
To determine if there was a quantitative difference in 
the amount of newly reverse-transcribed DNA in infected 
H9 and HL-60 cells, lysates from cells 6 hr after NL4-3 
or NL4-3 (M) infection were serially diluted and amplified 
using an 141V-l-specific primer pair (Fig. 30). As a quanti- 
tative control, cell lysates from serially diluted 8E5 cells 
(17) were amplified in parallel (Fig. 3D). Since each 8E5 
cell contains one provirus, a standard curve was gener- 
ated from the data shown in Fig. 3D using densitometric 
analysis. The samples shown in lanes 3, 6, and 9 of Fig. 
30 gave densitometric readings that fell in the linear 
portion of the curve and were used to calculate the num- 
ber of reverse-transcribed DNA copies per sample. There 
is a 3.6-fold higher amount of reverse-transcribed prod- 
uct in both NL4-3 (M)-infected HL-60 cells and NL4-3- 
infected H9 cells (23.7 copies/1 X 10 s cells) than in NL4- 
3-infected HL-60 cells (6.5 copies/1 x 10 s cells). These 
data are consistent with the &6-fold difference in the 
percentage of NL4-3-infected cells expressing viral anti- 
gens on the cell surface of H9 and HL-60 cells seen in 
the entry experiment (14% vs 4%) shown in Fig. 2. The 
results of this and three separate experiments using HIV- 
1-specific primer pairs R1/NO1 and poll/pol2 (18) varied 
by no more than 20% (3.67X, 3.64X, 17.5X, 3.56X) and 
consistently showed a higher amount of reverse-tran- 
scribed product in NL4-3-infected H9 cells than HL-60 
cells. These results, in conjunction with the result that 
the timing of entry of NL4-3 into H9 and HL-60 cells was 
similar, suggest that replication of NL4-3 in HL-60 cells 
was restricted at a step before reverse transcription. 
We have studied the early events in the life cycle of 
NL4-3 in the human myelomonocytic cell line, HL-60, as 
a model system for understanding the effect of a variant 
virus on different cell types. Our data, as well as those 
of others, show that HIV-1 can infect HL-60 cells (12, 22-  
25). In this study, we demonstrate that a variant virus, 
NL4-3 (M), can be consistently isolated during the lytic 
phase of infection of HL-60 cells. NL4-3 (M) is more cyto- 
pathic to myeloid cells than the parental virus, NL4-3. 
The phenotype of NL4-3 (M) is stable and not due to 
cytokines or other factors produced by HL-60 cells. 
Restricted growth of HIV-1 in different cell types can 
be the result of multiple, additive steps in the viral life 
cycle including the kinetics and efficiency of entry, intra- 
cellular steps in viral replication, and the magnitude of 
the viral burst. To analyze the first of these steps, we 
examined the kinetics of NL4-3 entry and reverse tran- 
scription in HL-60 and H9 ceils. These data demonstrate 
that NL4-3 enters HL-60 and Iq9 cells with identical kinet- 
ics; however, the number of completed reverse-tran- 
scribed molecules is consistently higher in H9 than in 
HL-60 cells. This suggests that there is a difference in 
the efficiency of steps in the viral life cycle before reverse 
transcription in these two cells lines. These results are 
similar to those of Kim etaL (26). Their data demonstrated 
that the quantity of linear viral DNA was 5- to 10-fold 
higher in H9 cells than in the human promonocytic cell 
line, U937. 
In addition to this restriction, the 10- to 15-day delay 
we observe~in the spread of NL4-3 in HL-60 cells com- 
pared to 149 cells suggests that there may be another 
restriction in the life cycle of NL4-3 in HL-60 cells that 
affects a step after viral entry, uncoating and reverse 
transcription. Recent studies by Mori et aL (27) demon- 
strate that when SIVmac239 is injected into rhesus mon- 
keys a variant, SlVmac316, arises which replicates more 
efficiently in macrophages than SIVmac239. We note that 
the phenotype of this virus is very similar to that of NL4- 
3 (M). Specifically, the investigators have quantitated the 
amount of newly synthesized viral DNA 14-16 hr after 
infection of alveolar macrophages and found that cells 
infected with SlVmac239 recombinant containing the en- 
velope gene of SlVmac316, SIVmac239/316ENV, have a 
threefold higher amount of newly synthesized viral DNA 
than cells infected with SlVmac239. In addition, since 
viral DNA increased dramatically between 14 and 66 hr 
after infection of alveolar macrophages with SIVmac239/ 
316ENV and not with SIVmac239, they conclude that the 
restricted replication of SlVmac239 in macrophages is 
due to a step in the viral life cycle after entry. Our results 
indicate that the restriction of NL4-3 in HL-60 cells is due 
in part to a reduction in the efficiency of viral entry into 
HL-6O cells. Furthermore, we suggest that later steps 
in the viral life cycle after reverse transcription may be 
affected and that the restricted phenotype of NL4-3 in 
myeloid cells is controlled by more than one viral gene. 
We also note that the viral variant, NL4-3 (M), produced 
during HL-60 cell infection overcomes all restrictions to 
viral replication in HL-60 cells. 
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